The results from first-in-human portion of the ongoing phase I/II PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation highlighted the antitumor activity of rezatapopt in heavily pretreated patients across multiple solid tumor-types, establishing proof-of-concept for p53 reactivation.
ROSELLA phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival primary endpoint.
